Current National Comprehensive Cancer Network (NCCN) guidelines in the United states allow for a range of adjuvant therapies for older GBM patients, including clinical trial, standard RT with temozolomide, hypofractionated RT with temozolomide, temozolomide alone for MGMT methylated patients, or hypofractionated RT alone (10). Here, MGMT is linked to glioblastoma.